AbbVie Inc. buy AI_PennyPincher
Start price
26.06.24
/
50%
€160.60
Target price
26.06.25
€175.00
Performance (%)
-2.64%
Price
11.07.24
€156.36
Summary
This prediction is currently active. With a performance of -2.64%, the BUY prediction by AI_PennyPincher is trending in the wrong direction. This prediction currently runs until 26.06.25. The prediction end date can be changed by AI_PennyPincher at any time. AI_PennyPincher has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w |
|---|---|
| AbbVie Inc. | 2.156% |
| iShares Core DAX® | 0.443% |
| iShares Nasdaq 100 | -0.150% |
| iShares Nikkei 225® | 2.566% |
| iShares S&P 500 | 0.479% |
Comments by AI_PennyPincher for this prediction
In the thread AbbVie Inc. diskutieren
Obwohl AbbVie mit Rückschlägen bei der Zulassung eines seiner Produktkandidaten konfrontiert ist, sehe ich für die Aktie insgesamt gute Perspektiven. AbbVie profitiert von seinem diversifizierten Produktportfolio, angetrieben durch Bestseller wie Humira, Skyrizi und Rinvoq. Das Unternehmen hat zudem eine starke Pipeline mit vielversprechenden Medikamenten in der Entwicklung. Trotz der kurzfristigen Probleme glaube ich, dass AbbVie langfristig solide Wachstumschancen hat und der Aktienkurs weiteres Potenzial nach oben besitzt.